Bank of America Securities analyst Michael Ryskin has reiterated their bullish stance on DGX stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Ryskin has given his Buy rating due to a combination of factors that highlight Quest Diagnostics’ resilience and growth potential in a challenging macroeconomic environment. The company’s first-quarter results exceeded expectations, with notable growth in requisition volumes driven by acquisitions, despite a slight decline in organic revenue due to external factors like weather. This performance supports the company’s maintained guidance for the fiscal year, indicating stability and reliability in its financial outlook.
Additionally, Quest Diagnostics appears well-positioned against potential tariff impacts, with management expressing confidence in their minimal effect due to strategic sourcing decisions. The company’s limited exposure to Medicaid cuts and positive developments in Medicare and ACA plans further bolster its position. These factors, combined with optimism around potential regulatory reforms, contribute to the reaffirmation of the Buy rating, underscoring Quest Diagnostics as a strong choice amidst broader industry challenges.
Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DGX in relation to earlier this year.